Protagonist Therapeutics, Inc. Common Stock PTGX
i
Market dataready · fetched 2026-11-07T07:27:26.916Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:04.749061374Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T07:27:26.427221+00:00
Protagonist Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 117.32 | 80.7% | 13.0% | |||
| 25Δ | 146.45 | 71.8% | 12.8% | 122.74 | 61.8% | 8.9% |
| 30Δ | 125.92 | 52.8% | 6.7% | |||
| 35Δ | 138.21 | 52.4% | 6.9% | 127.79 | 51.0% | 5.6% |
| 40Δ | 136.19 | 50.4% | 5.7% | 129.67 | 49.1% | 4.6% |
| 45Δ | 134.37 | 49.1% | 4.8% | 131.24 | 48.3% | 3.9% |
| 50Δ | 132.83 | 48.8% | 4.1% | 132.74 | 47.9% | 3.4% |
| 55Δ | 131.28 | 48.5% | 3.5% | 134.25 | 47.4% | 2.8% |
| 60Δ | 129.72 | 48.4% | 2.9% | 135.86 | 47.3% | 2.3% |
| 65Δ | 128.04 | 48.9% | 2.5% | 137.58 | 47.7% | 1.9% |
| 70Δ | 126.36 | 49.4% | 2.0% | 139.30 | 48.0% | 1.5% |
| 75Δ | 124.64 | 49.6% | 1.6% | 141.39 | 48.5% | 1.2% |
| 80Δ | 122.72 | 48.7% | 1.2% | 143.72 | 49.0% | 0.8% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 117.32
- IV
- 80.7%
- B/E move
- 13.0%
25Δ
- Pseudo strike
- 146.45
- IV
- 71.8%
- B/E move
- 12.8%
- Pseudo strike
- 122.74
- IV
- 61.8%
- B/E move
- 8.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 125.92
- IV
- 52.8%
- B/E move
- 6.7%
35Δ
- Pseudo strike
- 138.21
- IV
- 52.4%
- B/E move
- 6.9%
- Pseudo strike
- 127.79
- IV
- 51.0%
- B/E move
- 5.6%
40Δ
- Pseudo strike
- 136.19
- IV
- 50.4%
- B/E move
- 5.7%
- Pseudo strike
- 129.67
- IV
- 49.1%
- B/E move
- 4.6%
45Δ
- Pseudo strike
- 134.37
- IV
- 49.1%
- B/E move
- 4.8%
- Pseudo strike
- 131.24
- IV
- 48.3%
- B/E move
- 3.9%
50Δ
- Pseudo strike
- 132.83
- IV
- 48.8%
- B/E move
- 4.1%
- Pseudo strike
- 132.74
- IV
- 47.9%
- B/E move
- 3.4%
55Δ
- Pseudo strike
- 131.28
- IV
- 48.5%
- B/E move
- 3.5%
- Pseudo strike
- 134.25
- IV
- 47.4%
- B/E move
- 2.8%
60Δ
- Pseudo strike
- 129.72
- IV
- 48.4%
- B/E move
- 2.9%
- Pseudo strike
- 135.86
- IV
- 47.3%
- B/E move
- 2.3%
65Δ
- Pseudo strike
- 128.04
- IV
- 48.9%
- B/E move
- 2.5%
- Pseudo strike
- 137.58
- IV
- 47.7%
- B/E move
- 1.9%
70Δ
- Pseudo strike
- 126.36
- IV
- 49.4%
- B/E move
- 2.0%
- Pseudo strike
- 139.30
- IV
- 48.0%
- B/E move
- 1.5%
75Δ
- Pseudo strike
- 124.64
- IV
- 49.6%
- B/E move
- 1.6%
- Pseudo strike
- 141.39
- IV
- 48.5%
- B/E move
- 1.2%
80Δ
- Pseudo strike
- 122.72
- IV
- 48.7%
- B/E move
- 1.2%
- Pseudo strike
- 143.72
- IV
- 49.0%
- B/E move
- 0.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 39.43% | |
| 39.82% | |
| 39.94% | |
| 41.06% | |
| 41.15% | |
| 41.29% | |
| 40.99% | |
| 40.37% | |
| 40.03% | |
| 41.69% |
Biotechnology
PVLA
Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from specific gene mutations.…
More →PYPD
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address…
More →PYXS
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating…
More →QTTB
Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune response optimization.…
More →QURE
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in…
More →RANI
Description unavailable
More →